SMU-3k: Preclinical Efficacy Data for a Bifunctional STING Agonist/PD-L1 Inhibitor

3.2 KB of tabular data from a preclinical study on a bifunctional molecule named SMU-3k. The dataset, authored by Renjie Lin and last updated on 2026-04-22, likely contains results from experiments in the MC38 murine colon cancer model, demonstrating the molecule's ability to activate the STING pathway and block PD-1/PD-L1 interaction.

Use Cases

• Evaluating the synergistic antitumor efficacy of a bifunctional STING/PD-L1 inhibitor based on the described molecular conjugation strategy.
• Analyzing tumor growth inhibition data from the MC38 murine colon cancer model mentioned in the description.
• Investigating the relationship between STING pathway activation and PD-L1 upregulation as described in the study background.

Strengths

• Data is associated with a specific, novel therapeutic candidate (SMU-3k) described in the study.
• The dataset is small (3.2 KB), facilitating quick inspection and analysis.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (3.2 KB), indicating limited scope and likely a summary or subset of experimental results.

Provenance

Source

figshare, author Renjie Lin

Collection Method

Likely generated from laboratory experiments on the MC38 murine colon cancer model.

Freshness

Last updated 2026-04-22 12:38:16; freshness should be verified.